Compare Stocks: NMTR, MDCX, CVKD, and ADXN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$2.76 -8.6%	$3.81	$2.56 ▼ $11.97	$3.72M	1.52	14,056 shs	11,342 shs
CVKD Cadrenal Therapeutics	$1.09 +12.4%	$1.29	$0.82 ▼ $14.21	$3.46M	1.93	227,734 shs	172,917 shs
MDCX Medicus Pharma	$3.25 -5.2%	$9.65	$2.92 ▼ $139.00	$4.33M	0.3	85,558 shs	28,178 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	6 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+4.32%	-5.03%	-7.36%	-48.24%	-66.43%
CVKD Cadrenal Therapeutics	-4.90%	+4.35%	-7.62%	-55.09%	-93.10%
MDCX Medicus Pharma	+9.94%	-32.68%	-54.90%	-81.75%	-97.00%
NMTR 9 Meters Biopharma	0.00%	0.00%	0.00%	0.00%	+150.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$2.76 -8.6%	$3.81	$2.56 ▼ $11.97	$3.72M	1.52	14,056 shs	11,342 shs
CVKD Cadrenal Therapeutics	$1.09 +12.4%	$1.29	$0.82 ▼ $14.21	$3.46M	1.93	227,734 shs	172,917 shs
MDCX Medicus Pharma	$3.25 -5.2%	$9.65	$2.92 ▼ $139.00	$4.33M	0.3	85,558 shs	28,178 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	6 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+4.32%	-5.03%	-7.36%	-48.24%	-66.43%
CVKD Cadrenal Therapeutics	-4.90%	+4.35%	-7.62%	-55.09%	-93.10%
MDCX Medicus Pharma	+9.94%	-32.68%	-54.90%	-81.75%	-97.00%
NMTR 9 Meters Biopharma	0.00%	0.00%	0.00%	0.00%	+150.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	1,092.66% Upside
MDCX Medicus Pharma	2.50	Moderate Buy	$450.00	13,746.15% Upside
NMTR 9 Meters Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NMTR, MDCX, CVKD, and ADXN Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/15/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/2/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/2/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/14/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$210K	16.17	N/A	N/A	$4.67 per share	0.59
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.07 per share	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-174.44%	-126.47%	11/9/2026 (Estimated)
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
MDCX Medicus Pharma	-$35.46M	-$123.00	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A

Latest NMTR, MDCX, CVKD, and ADXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	N/A	MDCX Medicus Pharma	-$6.6250	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	CVKD Cadrenal Therapeutics	-$0.91	N/A	N/A	N/A	N/A	N/A
9/25/2026	Q2 2026	ADXN Addex Therapeutics	N/A	-$1.48	N/A	-$1.48	N/A	$0.01 million
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$6.3750	-$10.50	-$4.1250	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.76	0.76
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
MDCX Medicus Pharma	N/A	1.57	1.57
NMTR 9 Meters Biopharma	N/A	0.59	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CVKD Cadrenal Therapeutics	7.92%
MDCX Medicus Pharma	N/A
NMTR 9 Meters Biopharma	22.34%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CVKD Cadrenal Therapeutics	14.59%
MDCX Medicus Pharma	8.10%
NMTR 9 Meters Biopharma	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	3	1.23 million	1.05 million	Not Optionable
CVKD Cadrenal Therapeutics	5	3.57 million	3.05 million	Not Optionable
MDCX Medicus Pharma	16	1.26 million	1.16 million	N/A
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data

NMTR, MDCX, CVKD, and ADXN Headlines

Recent News About These Companies

What is a prepayment meter?

August 24, 2024 | uswitch.comU

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

July 28, 2024 | pharmaphorum.comP

Energy firms likely to miss smart meter deadline, warns Which?

December 14, 2023 | bbc.comB

Deal reached to sell some assets of bankrupt Raleigh firm

November 8, 2023 | bizjournals.com

9 Meters Biopharma, Inc. (NMTRQ)

November 7, 2023 | finance.yahoo.com

TRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 seconds

October 28, 2023 | asahi.comA

9 Meters Biopharma Inc (NMTRQ)

October 17, 2023 | investing.com

Vintage Meters Reborn As Steam Punk Clock

October 10, 2023 | hackaday.comH

9 Meters Biopharma (OTC: NMTR.Q)

August 16, 2023 | fool.com

Insider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?

July 25, 2023 | knoxdaily.comK

9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock Value

July 21, 2023 | knoxdaily.comK

Raleigh firm joins worrying trend of bankruptcies for drugmakers

July 18, 2023 | bizjournals.com

Drug developer 9 Meters Biopharma files for bankruptcy protection

July 18, 2023 | reuters.com

Why Are 9 Meters Biopharma Shares Nosediving Today?

July 18, 2023 | finance.yahoo.com

Examining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)

July 18, 2023 | knoxdaily.comK

Temperato resigns as CEO of Raleigh drugmaker

May 30, 2023 | bizjournals.com

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

May 30, 2023 | finance.yahoo.com

9 Meters Biopharma (NASDAQ: NMTR)

May 27, 2023 | fool.com

NMTR - 9 Meters Biopharma, Inc.

May 25, 2023 | uk.finance.yahoo.com

Citigroup Maintains 9 Meters Biopharma (NMTR) Neutral Recommendation

May 19, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, MDCX, CVKD, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$2.76 -0.26 (-8.61%)

Closing price 03:58 PM Eastern

Extended Trading

$2.80 +0.04 (+1.49%)

As of 07:05 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Cadrenal Therapeutics NASDAQ:CVKD

$1.09 +0.12 (+12.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.07 -0.02 (-1.74%)

As of 07:58 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Medicus Pharma NASDAQ:MDCX

$3.25 -0.18 (-5.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.39 +0.14 (+4.37%)

As of 07:56 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMTR, MDCX, CVKD, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMTR, MDCX, CVKD, and ADXN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMTR, MDCX, CVKD, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, MDCX, CVKD, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cadrenal Therapeutics NASDAQ:CVKD

Medicus Pharma NASDAQ:MDCX

9 Meters Biopharma NASDAQ:NMTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMTR, MDCX, CVKD, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMTR, MDCX, CVKD, and ADXN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMTR, MDCX, CVKD, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR, MDCX, CVKD, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cadrenal Therapeutics NASDAQ:CVKD

Medicus Pharma NASDAQ:MDCX

9 Meters Biopharma NASDAQ:NMTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools